Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar;182(3):1155-1162.
doi: 10.1007/s00431-022-04786-0. Epub 2023 Jan 5.

Changes of ECG parameters after BNT162b2 vaccine in the senior high school students

Affiliations

Changes of ECG parameters after BNT162b2 vaccine in the senior high school students

Shuenn-Nan Chiu et al. Eur J Pediatr. 2023 Mar.

Abstract

The purpose of this study is to determine the ECG parameter change and the efficacy of ECG screening for cardiac adverse effect after the second dose of BNT162b2 vaccine in young population. In December 2021, in cooperation with the school vaccination system of Taipei City government, we performed a ECG screening study during the second dose of BNT162b2 vaccines. Serial comparisons of ECGs and questionnaire survey were performed before and after vaccine in four male-predominant senior high schools. Among 7934 eligible students, 4928 (62.1%) were included in the study. The male/female ratio was 4576/352. In total, 763 students (17.1%) had at least one cardiac symptom after the second vaccine dose, mostly chest pain and palpitations. The depolarization and repolarization parameters (QRS duration and QT interval) decreased significantly after the vaccine with increasing heart rate. Abnormal ECGs were obtained in 51 (1.0%) of the students, of which 1 was diagnosed with mild myocarditis and another 4 were judged to have significant arrhythmia. None of the patients needed to be admitted to hospital and all of these symptoms improved spontaneously. Using these five students as a positive outcome, the sensitivity and specificity of this screening method were 100% and 99.1%, respectively. Conclusion: Cardiac symptoms are common after the second dose of BNT162b2 vaccine, but the incidences of significant arrhythmias and myocarditis are only 0.1%. The serial ECG screening method has high sensitivity and specificity for significant cardiac adverse effect but cost effect needs further discussed. What is Known: • The incidence of cardiac adverse effects was reported to be as high as 1.5 per 10 000 persons after the second dose BNT162b2 COVID-19 vaccine in the young male population based on the reporting system. What is New: • Through this mass ECG screening study after the second dose of BNT162b2 vaccine we found: (1) The depolarization and repolarization parameters (QRS duration and QT interval) decreased significantly after the vaccine with increasing heart rate; (2) the incidence of post-vaccine myocarditis and significant arrhythmia are 0.02% and 0.08%; (3) The serial ECG screening method has high sensitivity and specificity for significant cardiac adverse effect.

Keywords: Arrhythmia; BNT162b2 vaccine; ECG; Myocarditis; Screening.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Flow chart of the mass ECG screening and the case numbers. Overall, 70.8% of those willing to receive a second dose of BNT162b2 vaccine provided written informed consent and underwent pre-vaccine ECG. Among them, 87.6% (4928 students) underwent second ECG and completed the study. Because the students could request sick leave for the first 2 days after vaccination based on government policy, some of the students did not go to school and missed the second ECG screening. This flow chart also showed the brief outcome result in this study

References

    1. Center for systems Science and Engineering at Johns Hopkins University (2022) COVID-19 Dash board. https://coronavirus.jhu.edu/map.html. Accessed Apr 2022
    1. Centers for Disease Control and Prevention (CDC) (2021) Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-v.... Accessed Apr 2022
    1. Frenck RW, Jr, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, Perez JL, et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021;385:239–250. doi: 10.1056/NEJMoa2107456. - DOI - PMC - PubMed
    1. Centers for Disease Control and Prevention (CDC) (2021) Advisory Committee on Immunization Practices (ACIP). Coronavirus disease 2019 (COVID-19) vaccines. https://www.cdc.gov/vaccines/acip/meetings/slides-2021-2006.html. Accessed Apr 2022
    1. Husby A, Hansen JV, Fosbøl E, Thiesson EM, Madsen M, Thomsen RW, Sørensen HT, Andersen M, Wohlfahrt J, Gislason G, Torp-Pedersen C, Køber L, Hviid A. SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study. BMJ. 2021;375:e068665. doi: 10.1136/bmj-2021-068665. - DOI - PMC - PubMed